Acceptability Of Revised Study Expected To Be On Agenda For Northera Advisory Panel
This article was originally published in The Pink Sheet Daily
Executive Summary
Chelsea would address duration of effect questions for the neurogenic orthostatic hypotension drug with a post-approval study.